|
|
|
| home > epc > winter 2002 > assessing study feasibility in the netherlands - a research site's point of view |
|
|
 PUBLICATIONS |
European Pharmaceutical Contractor
|
Traditionally, sponsors have included feasibility checks in the process of choosing a study site. Sponsors often use standard feasibility forms for individual investigators as well as for SMO-type organisations. The ultimate goal of feasibility checking is to evaluate patient recruitment rate (in other words, number of patients to be randomised in a certain period) and to estimate costs.
In addition to the sponsor's validation of the research site, the site itself is responsible for undertaking a realistic and critical assessment of their resources and the type of study that is being offered, before deciding to accept the study for their research portfolio. The study's requirements and resources should also be assessed as accurately as possible from a regulatory point of view.
Regulation ICH 4.2 demands that an investigator should "be able to demonstrate a potential for recruiting the required number of suitable patients; to have sufficient time to properly conduct and complete the study within the agreed trial period and have an adequate, well informed staff with adequate facilities." When a site moves from participating in one study at a time to several studies simultaneously it has an impact on space, staff, patient recruitment systems and so on.
|
Read full article from PDF >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
 |
Industry Events |
 |
Paediatric Clinical Trials
21-22 March 2012, Copthorne Tara Hotel, London, United Kingdom
Designing accurate and safe paediatric formulations is one of the topics being discussed at SMi’s Paediatric Clinical Trials held on 21st & 22nd March 2012
More info >> |
|
 |
News and Press Releases |
 |
Pantec Biosolutions to Present P.L.E.A.S.E.® Professional for Transdermal Drug Delivery at DDP in Las Vegas
Pantec Biosolutions AG, the developer and manufacturer of P.L.E.A.S.E.® Professional, a state of the art portable laser device that sets new standards for safety, precision and versatility, today announced that it will be giving a scientific company presentation during the “Drug Delivery Partnerships” conference from 25th -27th January 2012 in Las Vegas, USA.
More info >> |
|
|
